How Trulicity Lowers Blood Sugar in Diabetes
Trulicity (dulaglutide) is a once-weekly injectable medication approved for type 2 diabetes. It mimics GLP-1 (glucagon-like peptide-1), a gut hormone that regulates blood sugar. By activating GLP-1 receptors, it triggers insulin release from the pancreas when glucose levels are high, while suppressing glucagon—a hormone that raises blood sugar. This dual action reduces fasting and post-meal glucose without causing low blood sugar (hypoglycemia) when used alone.[1]
Why It Also Aids Weight Loss
Trulicity slows stomach emptying, increasing feelings of fullness and reducing appetite. Patients often lose 2-6 pounds over 6 months, which helps with insulin sensitivity in overweight individuals with type 2 diabetes.[1][2]
How It Fits into Diabetes Treatment
Doctors prescribe Trulicity alongside diet, exercise, metformin, or other drugs like SGLT2 inhibitors. Clinical trials (e.g., AWARD series) showed A1C reductions of 0.7-1.6% over 26-52 weeks, outperforming placebo and some oral meds. It's not for type 1 diabetes or diabetic ketoacidosis.[1][3]
Common Side Effects Patients Experience
Nausea (most frequent, often fades), vomiting, diarrhea, and abdominal pain affect 10-20% of users initially. Rare risks include pancreatitis, thyroid tumors (boxed warning), or gallbladder issues. Monitor for injection-site reactions.[1][2]
Who Makes Trulicity and When Patents Expire
Eli Lilly manufactures Trulicity. Key U.S. patents expire around 2033-2034, with challenges from generics like those from Dr. Reddy's. Exclusivity ends December 2026.[4]
Sources
[1] Trulicity Prescribing Information (FDA)
[2] ADA Standards of Care 2023
[3] NEJM: AWARD-3 Trial
[4] DrugPatentWatch.com - Trulicity Patents